This suggestion was made when $75m
marketing costs was first announced.
Hopefully E4 does have some clear
advantages. With Mithra SP fading it
doesn’t appear to be shooting any lights
out in Europe or the many other countries
where approved. It will definitely need some
clear advantage over womens existing choice
. Just ask your wife or girlfriend for their opinion.
- Forums
- ASX - By Stock
- Ann: 2022 Half Year Investor Presentation
MYX
mayne pharma group limited
Add to My Watchlist
2.19%
!
$4.92

This suggestion was made when $75mmarketing costs was first...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.92 |
Change
-0.110(2.19%) |
Mkt cap ! $399.7M |
Open | High | Low | Value | Volume |
$5.03 | $5.03 | $4.86 | $1.730M | 352.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100 | $4.88 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.93 | 25000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 6000 | 4.870 |
2 | 10000 | 4.860 |
3 | 51300 | 4.850 |
1 | 600 | 4.840 |
2 | 2800 | 4.800 |
Price($) | Vol. | No. |
---|---|---|
4.930 | 25000 | 1 |
4.960 | 1303 | 1 |
4.980 | 1303 | 1 |
5.000 | 1303 | 1 |
5.020 | 1303 | 1 |
Last trade - 16.15pm 23/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |